Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 4
2016 10
2017 20
2018 23
2019 31
2020 37
2021 60
2022 77
2023 20
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 33158904

223 results

Results by year

Filters applied: . Clear all
Page 1
Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L. van Leeuwen PJ, et al. BJU Int. 2019 Jul;124(1):62-68. doi: 10.1111/bju.14506. Epub 2019 Apr 7. BJU Int. 2019. PMID: 30074667
Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, Sedelaar JPM, Küsters-Vandevelde HVN, Gotthardt M, Wijers CHW, van Basten JP, Somford DM. Baas DJH, et al. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):65-70. doi: 10.1038/s41391-021-00452-y. Epub 2021 Sep 1. Prostate Cancer Prostatic Dis. 2022. PMID: 34471231
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
Meijer D, Eppinga WSC, Mohede RM, Vanneste BGL, Meijnen P, Meijer OWM, Daniels LA, van den Bergh RCN, Lont AP, Ettema RH, Oudshoorn FHK, van Leeuwen PJ, van der Poel HG, Donswijk ML, Oprea-Lager DE, Schaake EE, Vis AN. Meijer D, et al. Eur Urol Oncol. 2022 Apr;5(2):146-152. doi: 10.1016/j.euo.2022.01.001. Epub 2022 Jan 22. Eur Urol Oncol. 2022. PMID: 35074282 Free article.
Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
Rogowski P, Trapp C, von Bestenbostel R, Eze C, Ganswindt U, Li M, Unterrainer M, Zacherl MJ, Ilhan H, Beyer L, Kretschmer A, Bartenstein P, Stief C, Belka C, Schmidt-Hegemann NS. Rogowski P, et al. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1417-1428. doi: 10.1007/s00259-021-05557-z. Epub 2021 Oct 10. Eur J Nucl Med Mol Imaging. 2022. PMID: 34628521 Free PMC article.
The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
Meijer D, Ettema RH, van Leeuwen PJ, van der Kwast TH, van der Poel HG, Donswijk ML, Oprea-Lager DE, Bekers EM, Vis AN. Meijer D, et al. BJU Int. 2023 Mar;131(3):330-338. doi: 10.1111/bju.15881. Epub 2022 Sep 17. BJU Int. 2023. PMID: 36069585
223 results